Phase I-II FIH TROP2 ADC Advanced Unresectable/Metastatic Solid Tumors Refractory to Standard Therapies

Study Overview

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:

i. Ovarian epithelial cancer (Phase I only) ii. Gastric adenocarcinoma (Phase I-II) iii. Pancreatic adenocarcinoma (Phase I-II) iv. Triple negative breast cancer (Phase I only) v. Bladder cancer (Phase I-II)

Study Description

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced/Metastatic Solid Tumors who are refractory to Available Standard Therapies

  • ClinicalTrials.gov Identifier: NCT04152499
  • Protocol Number: 19-600

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000